- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology Europe-11-01-2008
Pharmaceutical Technology Europe
Developing nanoparticle formulations or poorly soluble drugs
November 01, 2008
Formulation
20
11
Rapid advances in drug discovery have led to the identification of a number of compounds with good therapeutic potential.
Is Pharma recession-proof?
November 01, 2008
Viewpoint
20
11
I confess I am no financial expert. My knowledge about the current credit crisis can be summed up in six words: 'debt is bad; cash is good', which was pretty much the limit of my understanding about money before it all began.
20th Anniversary Special Feature: The impact of regulations
November 01, 2008
Validation
20
11
During the past two decades, regulations have evolved in both Europe and the US to accommodate the technological developments in the pharmaceutical, biotechnology and medical device industries.
New Jersey
November 01, 2008
Business
20
11
More than 235 biotechnology companies call New Jersey home. They range from early start-ups with just a few employees to fully functioning companies with research, marketing and sales offices.
Michigan
November 01, 2008
Business
20
11
Although California remains the country's biotech leader, Michigan anticipates that the wind is shifting direction, albeit slowly
Manufacturing problems
November 01, 2008
Surface Surgery
20
11
Many industries, from aerospace to medical devices, conduct cleaning procedures.
The beginning of the end
November 01, 2008
Spotlight
20
11
There are many challenges upstream and downstream in manufacturing a biotech drug.
It's showtime
November 01, 2008
20
11
The first 2 weeks of October witnessed the closure of CPhI (30 September–2 October) and the whole of Biotechnica (7–9 October). Pharmaceutical Technology Europe had a presence at both events, which took place in Frankfurt and Hanover (both Germany), respectively. With record-breaking numbers of attendees, roundtables and conferences of the highest quality, and exhibitors from bio and pharma companies from all over the world, these two events are a must in the calendars of many in the biotech and pharmaceutical industries.
Pennsylvania
November 01, 2008
Business
20
11
Richard Kilner, Managing Director of the Commonwealth of Pennsylvania European Investment Office, is incredibly enthusiastic about both his State and the potential it offers investors: "We are the number one State in pharmaceuticals (by number of establishments, employment and GDP output) and rapidly closing in on Massachusetts, the number two in biotech."
All change for drug distribution
November 01, 2008
Outsourcing review
20
11
Together, Europe and the US account for more than 70% of the global pharmaceutical market, and the growth of these markets is heavily dependent on distribution systems.
Western promises
November 01, 2008
Business
20
11
Access to the capital markets of the US has always been a key attraction for Europe's biotech businesses.
Rapid and convenient microsphere sizing
November 01, 2008
PAT
20
11
FDA advocates building quality into a product through PAT.
Zebrafish: a multifaceted approach for drug safety assessment
November 01, 2008
Biopharmaceuticals
20
11
Many compounds fail in preclinical development because of safety-related problems, but identifying 'predictable' safety or toxicity liabilities earlier in the process could lead to improved design and selection of compounds that are more likely to be approved.
Reaping the benefits of assay miniaturization
November 01, 2008
Manufacturing & Processing
20
11
Efficiency is more than just a buzzword in today's pharmaceutical industry; declining productivity and diminishing returns on investment have made it an over-arching mindset that is critical to corporate survival.
California
November 01, 2008
Business
20
11
California's forward-thinking reputation, well-funded research universities and world leadership in the potentially life-saving field of stem cell research and green energy provide a progressive and positive business environment for biotech companies.
Why the future is in fragments?
November 01, 2008
Talking Point
20
11
High-throughput screening (HTS) of compound libraries is the most widely adopted approach to hit discovery because it is the only generic way of addressing a variety of targets on an industrial scale.
Georgia
November 01, 2008
Business
20
11
Speaking to Pharmaceutical Technology Europe, Georgia Bio's Director of Innovation and Technology, Carol Henderson, outlined the unique assets that make Georgia an attractive location for international bioscience companies.
Florida
November 01, 2008
Business
20
11
According to Deputy Director, Alexander Bothmann, of Enterprise Florida Inc., in Germany, the 'Sunshine State' is: "Committed to building a world-class biotechnology sector by investing in research facilities, fostering the growth of local biotech companies and welcoming progressive newcomers, such as the Scripps Research Institute, the Burnham Institute for Medical Research and Torrey Pines Institute for Molecular Studies."